The prognostic value of hospital-managed Multidisciplinary Teams in metastatic castration-sensitive prostate cancer cases

Background In oncology, Multidisciplinary Teams (MDTs) are pivotal. However, evidence is scarce on the prognostic impact of hospital-managed MDTs, particularly in male metastatic castration-sensitive prostate cancer (mCSPC) cases. Our study aims to determine if hospital-driven MDTs act as a distinct, independent prognostic factor in this context. Methods This retrospective analysis at the Oncology Center of the First People’s Hospital of Yulin focused on patients with mCSPC, documenting their clinical and pathological characteristics. Implementing a hospital-managed Multidisciplinary Team (MDT) model, patients had the option to engage in multifaceted interventions. Survival outcomes were analyzed using Kaplan-Meier and log-rank tests for group comparisons, and Cox proportional hazards models, adjusted for baseline features, estimated hazard ratios for overall survival (OS), with statistical significance at P  < 0.05. Results Data were available for 227 mCSPC and 76.2% were treated under hospital-managed MDT. mCSPC typically presents with elevated prostate-specific antigen levels, bone metastases, and lymph node involvement. Non-MDT patients experienced significantly reduced overall survival (OS) (32.6 vs. 45.5 months, P  < 0.001) and progression-free survival (PFS) (22.7 vs. 35.8 months, P  < 0.001) compared to those receiving MDT. The favorable influence of hospital-managed MDT on OS was maintained even after controlling for CHAARTED or LATITUDE risk stratification and other crucial baseline prognostic variables. Conclusions These results highlight the beneficial prognostic influence of hospital-managed MDT in mCSPC patients, necessitating prospective research for validation.